SavedAdd your journal

Journals / Türk Kardiyoloji Derneği Arşivi / 2017 / Cilt: 45 - Sayı: Suppl. 1 (Özel Sayı)

in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–61. 5. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes

6. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, et al. Eff ects of fi brates on cardiovascular outcomes: a systematic

Ayşe Naciye ERBAKAN
Aytekin OĞUZ
Pages
36–39
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sacks FM, Carey VJ, Fruchart JC.
📊
Key Findings & Data:Combination lipid therapy in type 2 diabetes.
💡
Conclusion & Impact:Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

9. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692–4. 10. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic

Özet

Anti-apoptotik ??AMP aktive protein kinaz ?/AMP aktive protein kinaz Endotel kaynaklı nitrik oksit sentaz ? IGF1R yaşam sinyalizasyonu ?Endotel hücre apoptozu hücre apoptozu ?Retinal pigment epitel

🔖

Cite This Article

ERBAKAN, A. N., OĞUZ, A. (2022). in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–61. 5. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes. Türk Kardiyoloji Derneği Arşivi, Cilt: 45 - Sayı: Suppl. 1 (Özel Sayı), 36–39. https://ajindex.com/articles/632547

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes--insight from the FIELD study. Curr Pharm Des 2009;15:537–52
  2. Keating GM. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am J Cardiovasc Drugs 2011;11:227–47
  3. Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes 2013;62:3968–75
  4. Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687–97
  5. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233–44
  6. Mitsiou EK, Athyros VG, Karagiannis A, Mikhailidis DI. Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? Open Cardiovasc Med J 2012;6:28–32
  7. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45:485–93
  8. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012;35:1008–14
  9. Tesfaye S, Selvarajah D. The Eurodiab study: what has this taught us about diabetic peripheral neuropathy? Curr Diab Rep 2009;9:432–4
  10. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D’Emden MC, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780–8.